In this phase 2 randomized trial, the CD38 monoclonal antibody felzartamab showed acceptable safety and promising efficacy among patients with chronic antibody-mediated kidney-transplant rejection.
The New England Journal of Medicine: Search Results in Allergy/Immunology
